ackground to the debate: An important mechanism for protecting human research participants is the prior approval of a clinical study by a research ethics board, known in the United States as an institutional review board (IRB). Traditionally, IRBs have been run by volunteer committees of scientists and clinicians working in the academic medical centers where the studies they review are being carried out. However, for-profi t organizations are increasingly being hired to conduct ethics reviews. Proponents of for-profi t IRBs argue that these IRBs are just as capable as academic IRBs at providing high-quality ethics reviews. Critics argue that for-profi t IRBs have a confl ict of interest because they generate their income from clients who have a direct fi nancial interest in obtaining approval.
Why might we think that for-profi t IRBs do these functions poorly? Perhaps being for-profi t, they need to woo business, and so they are less independent of their clients, less inclined to be critical, and more inclined to overlook ethical problems.
But these potential diffi culties are not unique to for-profi t IRBs. Researchers who sit on not-for-profi t, academic IRBs are evaluating their colleagues' research protocols, so these IRB members also have ties that may compromise their independence and critical evaluations. Furthermore, many academics tend to view IRB service as an uncompensated burden, which is not conducive to careful review work. Academic medical centers and their researchers also have their own fi nancial interests in getting research protocols passed. They get money-as well as access to new drugs and prestige-for conducting the research. Many not-for-profi t IRBs are also charging drug and device companies for review of their research protocols, and their rates are comparable to the rates charged by for-profi t IRBs.
The crucial question is whether an IRB, regardless of its tax status, is performing at a high level of quality. Unfortunately, there are no validated quality indicators for IRB function, and no head-to-head comparison has been made of the performance of for-profi t and not-for-profi t IRBs. However, to evaluate the quality of IRB function we have some approximate indicators such as regulatory compliance, accreditation, knowledge sharing, and internal quality assurance practices.
In recent years the US's Offi ce for Human Research Protections (OHRP) has suspended, at least temporarily, the research being conducted at a number of major medical centers-including Johns Hopkins, Duke University, Rush University, University of Colorado, and University of Rochester. Furthermore, unexpected deaths in research participants that have captured the public eye have occurred at some of these same institutions-Johns Hopkins and University of Rochester-as well as at the University of Pennsylvania and Case Western Reserve University. The suspension of research by OHRP and the unexpected death of relatively healthy research participants are not perfect indicators of poor studies or poor IRB performance, but neither can they be dismissed as irrelevant. All of these prominent cases have occurred at not-for-profi t academic institutions.
The fi rst IRBs to receive "full accreditation"-the highest level of accreditation awarded by the Association for the Accreditation of Human Research Protection Programswere one for-profi t IRB, Western Institutional Review Board (WIRB), and one not-for-profi t IRB, University of Iowa. And so it continued: of the fi rst eight organizations to receive full accreditation, four were for-profi t IRBs.
At least 26 academic institutions outsource all or part of their protocol review to for-profi t IRBs. And in recent years, the OHRP has called upon WIRB to re-review protocols and revamp the IRB processes and procedures at not-for-profi t academic institutions where the OHRP had temporarily suspended research. Calling upon WIRB constitutes a vote of confi dence by federal regulators that at least this one for-profi t entity provides high-quality IRB review, and has something to teach the not-for-profi t academic centers about institutionalizing quality IRB review.
Furthermore, OHRP has never suspended a for-profi t IRB. And, the US Food and Drug Administration (FDA) has issued only one warning letter to a for-profi t IRB compared to hundreds to IRBs at not-for-profi t institutions.
For-profi t IRBs have made contributions to the common good. For example, WIRB has established a program allowing IRB administrators from developing countries in Latin America, Southeast Asia, South Asia, and other places to visit their location for six months of training in running an IRB. So far, 24 fellows have been trained. How many not-for-profi t IRBs have established programs to improve protocol review either in the US or other countries using their own moneynot grants from the National Institutes of Health?
Making a distinction about the quality and merits of IRBs based on tax status is an antiquated piece of ideology reminiscent of Orwell's Animal Farm-"for-profi t bad, notfor-profi t good."
The distinction obscures what we should care about and directly measure-the quality of IRB review of protocols and the monitoring of the safety of research participants. There are absolutely no data showing that either independence of reviewers or quality outcomes are correlated with an IRB's profi t status, and there is some real evidence in the regulatory actions and accreditation that the quality of for-profi ts is as good as or better than many of their not-forprofi t academic counterparts. Since we are supposed to be researchers and driven by data not emotion, let's give up the crude ideology and stick to the data.
Trudo Lemmens and Carl Elliot's Viewpoint: Commercial IRBs Have a Fundamental Confl ict of Interest
Like it or not, research on humans has become a commercial enterprise. Most clinical trials have moved from academic settings to specialized contract research organizations (CROs), which contract with the pharmaceutical and biotechnology industries. Whereas 63% of clinical trials were still being undertaken in academic settings in 1994, a mere 26% of such trials remained there in 2004 [1] .
It is widely recognized that the commercialization of medical research creates serious confl icts of interest [2] [3] [4] [5] . What is often overlooked is that IRB review, which is often expected to provide protection against such confl icts, has also become commercialized. Some industry-funded trials are reviewed by in-house IRBs set up and funded by pharmaceutical companies or CROs themselves; others are reviewed by commercial, for-profi t IRBs [6] . Of course, commercial IRBs are not an entirely new phenomenon. The oldest and most successful IRB, WIRB, has been in business since 1968. What is new about commercial IRBs is their extraordinary reach. According to its founder, WIRB is now responsible for the review of more than half of all new drug submissions to the FDA [7] . Several universities and hospitals also outsource ethics review to commercial IRBs.
Yet commercial IRBs have a fundamental confl ict of interest [5, [8] [9] [10] [11] . They are in a client-provider business relationship with the commercial entities whose studies they review. Because commercial IRBs generate their income from clients with a direct fi nancial interest in obtaining approval, they are affected by the very problem they are expected to curtail. The fi nancial interests involved are huge. Pharmaceutical companies pay CROs for their speed and effi ciency. Clinical trials are a crucial step in the drug development process. Any delay in approval by an IRB affects the sponsor's profi t margins.
The countries that have allowed these private IRBs to fl ourish have also failed to regulate them carefully. Neither the US nor Canada has placed any serious restrictions on the establishment of new IRBs. Although an IRB registry has recently been set up for federally funded research in the US, and although the FDA and Health Canada sporadically inspect IRBs involved in the review of clinical trials, they do not have formal registration and approval processes for IRBs. Anyone who can bring together fi ve people, including a community representative, a physician, a lawyer and an "ethicist," can set up shop and start competing for business.
Moreover, regulations in those countries fail to prevent CROs from selecting the IRB least likely to reject the trial or delay approval by imposing too many restrictions. If one IRB is too stringent, they can simply go to the one next door.
Free market advocates will argue that the research industry has an interest in promoting quality IRB review. In theory, sound ethical review could prevent lawsuits, and commercial IRBs could use ethical review as a marketing tool. In fact, however, commercial IRBs market their speed and effi ciency, and lawsuits are still relatively rare. Most are settled out of court, with the records sealed from public view. Moreover, the costs of these lawsuits pale in comparison with the profi t gained by bringing a new drug faster to market. For multinational pharmaceutical companies, litigation is a manageable cost of doing business.
Commercial IRBs fi ll a regulatory vacuum in countries that lack a governmentally organized system of ethics review. Yet, as Bloomberg Markets reported, several commercial IRBs have approved and been involved in overseeing controversial research practices. SFBC International, the largest CRO in the United States, has recruited undocumented immigrants to a converted motel in Miami and paid them to enroll in trials overseen by an unlicensed medical director [7] . Some of SFBC International's clinical trials were approved by a now dismantled commercial IRB owned by the wife of an SFBC International vice president [7] . To oversee the research conducted at the Fabre Research Clinic, the clinic's owner founded a private IRB that had his business partner and lawyer as members. The clinic was eventually shut down by the FDA after an investigation into the death of a research participant and more than ten years after the agency fi rst fl agged several serious research irregularities [12] . In another article, Bloomberg Markets reported that a Canadian affi liate of SFBC International, Montreal's Anapharm, is currently being investigated by the Canadian drug regulatory authorities after several human research participants were infected with tuberculosis. Research participants had been submitted to basic medical screening, according to the report, but not to any specifi c tests for tuberculosis, even though the trial involved an immunosuppressant drug [13] .
In 1999, Swiss authorities were alerted that a CRO in the Canton Basel was recruiting individuals from Eastern Europe and asylum seekers as research participants for Swiss clinical trials. An investigation conducted by a special working group for the drug regulatory agency revealed troubling consent procedures, such as consent forms being in languages the trial participants did not understand. The principal investigator for the clinical trials, who combined the position of CRO director with that of local director of the commercial IRB that approved the research, was not licensed to practice medicine [14] .
At a time when commercial interests threaten the safety of research participants and the integrity of medical research, it is remarkable that North American regulatory agencies have not seen any problem with entrusting the rights and wellbeing of human research participants to a lightly regulated commercial enterprise. In the wake of the Swiss scandal, the authorities in Basel introduced new regulations requiring registration and regulatory approval of IRBs. IRBs also received exclusive jurisdiction, making it impossible to shop for the most lenient IRB. These new regulations, under which no commercial IRBs were approved, were upheld by the Swiss Supreme Court. The court argued that research ethics committees fulfi ll a public function with a direct mandate from the state [15, 16] . It is time for regulatory authorities in Canada and the US to follow suit. The protection of research participants is a critically important public mandate, and it merits a truly independent regulatory structure.
Emmanuel's Response to Lemmens and Elliot's Viewpoint
I agree with Lemmens and Elliot that "the protection of research subjects is a critically important public mandate, and it merits a truly independent regulatory structure." That is where the agreement ends.
Lemmens and Elliot claim that "commercial IRBs have a fundamental confl ict of interest." But IRBs at academic medical centers have even greater confl icts of interest [17] . Both commercial and academic IRBs have a fi nancial confl ict of interest, especially since increasingly academic IRBs are charging competitive prices for their services, making them indistinguishable from commercial IRBs. Academic IRBs have the additional confl ict that the researchers being reviewed are colleagues of the IRB members. And they have yet a further confl ict since the institution wants and needs the commercial research in order to gain access to new drugs and devices to enhance its reputation as innovative.
Lemmens and Elliot confl ate CROs and commercial IRBs, trying to tar the reputation of commercial IRBs with unsavory practices of CROs. Furthermore, when all the hyperbole is ignored, these authors base all their objections on just three anecdotes, rather than on rigorous scientifi c data. That the owners/operators of SFCB, Fabre Research Clinic, and a research center in Switzerland have been accused of unscrupulous practices hardly constitutes an indictment of all commercial IRBs. Using similar logic one might indict all notfor-profi t IRBs because of the documented poor performance of academic IRBs that had to be suspended at Johns Hopkins, Duke University, University of Colorado, University of Rochester, etc.
Lemmens and Elliot marshal absolutely no scientifi c data to show that any of the major commercial IRBs in the US-including WIRB, Schulman, Chesapeake, Essex, and Copernicus-are performing poorly. The authors cite no studies, for example, to show that the quality of the reviews by these IRBs is poor or that these IRBs have approved unethical studies. I do not know whether these IRBs are all good, but if Lemmens and Elliot's broad indictment leveled against all commercial IRBs is valid, they surely should provide data about the poor quality of the major commercial IRBs, since these account for the majority of reviews done in the commercial sector. Otherwise, the charges appear to be good headlines, but are baseless.
Finally, despite their rhetoric, Lemmens and Elliot do not actually call for the prohibition of commercial IRBs. They want more regulatory oversight. Yet, I am unaware of their having delineated a comprehensive proposal describing such an oversight system. With Wood and Grady, I have proposed a system of regional ethics organizations that would review and monitor research protocols, educate researchers on the ethics of human research, and develop policies in controversial areas, such as paying participants [18] . Such organizations would completely eliminate confl icts of interest, fi nancial and otherwise, between the reviewing organizations and researchers. Maybe this is something Lemmens and Elliot can agree with? If not, let's hear their positive proposal for a "truly independent regulatory structure."
Lemmens and Elliott's Response to Emanuel's Viewpoint
Not too long ago, an article on the protection of sick and vulnerable research participants that compared the funding of IRBs to the funding of for-profi t jails would have been read as satire. In North America today, however, where medical research happily converges with consumer capitalism, even bioethicists believe that the market ultimately works for justice. Do we need to point out that the problem with the consumerist model for protecting research participants is not, as Emanuel suggests, its "tax status"? The problem is that commercial IRBs are paid in full by the very companies conducting the research. What is more, those companies are free to shop around for any IRB whose reviews they fi nd congenial. Research participants who are worried that they may face death or injury in a study sponsored by a pharmaceutical company are unlikely to feel more secure knowing that their safety has been entrusted to a panel of paid experts whose fi nancial livelihood depends on a company paycheck.
Acknowledging that no good data exist to compare commercial and university IRBs, Emanuel nevertheless exhorts us to "stick to the data" anyway, recommending the example of WIRB, a commercial IRB that earned $20 million in 2004, and whose president was Emanuel's research collaborator (as he acknowledges in his competing interests statement). Yet part of the data he omits from his enthusiastic recommendation comes from Bloomberg Markets, which reported in December that WIRB "oversaw tests in California and Georgia in the 1990s for which doctors were criminally charged and jailed for lying to the FDA and endangering the lives of trial participants. No action was taken against WIRB" (p. 37 of [7] ). The same report revealed that WIRB had settled a lawsuit after it approved a placebo-controlled trial for a Genentech psoriasis drug in which a patient was severely injured, that it had drawn criticism from the FDA in inspection visits, and that on one occasion, when reviewing protocols for Johns Hopkins University, it reversed a previous decision under pressure from a clinical sponsor, using a panel dominated by alternate members.
It is rarely, if ever, possible to know whether fi nancial incentives have improperly infl uenced a member of an IRB. This uncertainty is the reason for rules about confl icts of interest-to prevent people from being placed in situations where they are likely to be improperly infl uenced. We agree with Emanuel that academic IRBs are marred by many of the same problems facing for-profi t IRBs, including confl icts of interest [6, 19] . But the problems of academic IRBs do not make those of for-profi t IRBs disappear. The proper solution is to clean up the confl icts of interest, not to institute a replacement in which such confl icts are built right into the system.
